The Image-guided Biopsy Market has showcased steady growth, with a valuation of USD 2266.21 million in 2022. Forecasts suggest continued expansion, with expectations to reach USD 3386.68 million by 2030, marked by a compound annual growth rate (CAGR) of 5.15% throughout the forecast period from 2023 to 2030. This growth trajectory reflects the increasing adoption of image-guided biopsy procedures, driven by advancements in imaging technologies, rising incidence of cancer and other diseases requiring biopsy for diagnosis and treatment planning, and the growing demand for minimally invasive techniques. As healthcare providers and patients alike recognize the benefits of precision medicine and targeted therapies, the image-guided biopsy market is poised for sustained growth, offering opportunities for improved diagnostic accuracy and patient outcomes.